Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Current HIV Research|June 3, 2011
Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infectionsFernando Dronda, Paz Sobrino, Beatriz Hernández-Novoa, et al.
Antiviral Research|June 12, 2012
No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patientsFederico Alejandro Di Lello, Juan Macias, Zulema Plaza, et al.
AIDS (London, England)|May 4, 2011
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapsePablo Labarga, Pablo Barreiro, José A Mira, et al.
The Journal of Infectious Diseases|June 2, 2011
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunctionSudeep P Pushpakom, Neill J Liptrott, Sonia Rodríguez-Nóvoa, et al.
AIDS (London, England)|March 8, 2011
Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patientsPablo Labarga, Vincent Soriano, Antonio Caruz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 27, 2011
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis CNorma I Rallón, Judit Morello, Pablo Labarga, et al.
HIV Clinical Trials|October 25, 2007
Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAARTJulio Arrizabalaga, Piedad Arazo, Koldo Aguirrebengoa, et al.
AIDS (London, England)|April 2, 2005
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosineAna Barrios, Ana Rendón, Eugenia Negredo, et al.
The Journal of Infectious Diseases|July 19, 2012
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trialPablo Labarga, Pablo Barreiro, Alfredo da Silva, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 15, 2004
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]José Antonio Iribarren, Pablo Labarga, Rafael Rubio, et al.
Pageof 11